pentapeptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
Human data remain limited and come mainly from small, short-term studies conducted decades ago. The peptide has not received approval as a medicine from major regulators, so current availability is largely as a research chemical. Reported effects on growth hormone pulsatility, appetite, and body composition should be read as preliminary, since few independent groups have replicated the original findings. Analytical characterization of research-grade material varies between suppliers, which complicates comparison across studies. Regulatory status also differs by country, and some jurisdictions classify it as a prescription-only or otherwise restricted item.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic pentapeptide | Chain of five amino acid residues |
| Molecular mass | Approximately 712 Da | Consistent with a five-residue chain |
| Receptor target | GHS-R1a | Growth hormone secretagogue receptor |
| Primary action | Growth hormone release | Pituitary somatotroph stimulation |
| Research origin | Developed in the 1990s | Small-peptide secretagogue program |
In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.
Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, and its molecular mass is approximately 711.9 daltons. The compound was described in the late 1990s by researchers seeking molecules that release growth hormone with fewer side effects than earlier secretagogues. It is a laboratory and research compound, not an approved medicine in most jurisdictions.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.
杂质谱一般包含缺失序列片段、差向异构体、氧化产物以及残留溶剂或反离子，其中组氨酸与芳香残基的氧化常被重点关注。反相色谱中这类杂质往往紧邻主峰洗脱，因此方法需要足够的分离度并经过系统适用性验证。纯度百分比的解读依赖于检测波长与梯度条件，不同实验室公布的数字不宜直接横向比较。参考标准品有助于跨批次对照，但其自身赋值同样需要可追溯来源。
冻干状态下的肽通常比溶液状态更稳定，常规做法是维持 -20 °C 或更低温度、保持干燥并避开强光。复溶后的降解主要来自水解、氧化与脱酰胺，速率受 pH、缓冲液种类、离子强度与温度共同影响，碱性条件一般会加快这些反应。反复冻融会造成聚集与容器吸附损失，分装保存能降低该风险。容器材质与金属离子也可能参与氧化过程，需与操作条件一并考虑。
对 ipamorelin 的常规表征以反相高效液相色谱测定纯度，检测波长多设为 214 nm，因为肽键在该波长有较强吸收。身份确认通常借助电喷雾电离质谱或串联质谱，将实测分子量与理论值逐项比对。序列层面可用肽图分析或氨基酸分析进一步验证。这些手段组合起来，可以分别覆盖纯度、身份与序列三个不同层次的信息。
Identity and purity are assessed by complementary methods rather than a single test. Reversed-phase high-performance liquid chromatography separates the peptide from related impurities and reports a percentage purity. Mass spectrometry, most often with electrospray ionization, confirms the expected molecular mass and detects sequence-related variants. Amino acid analysis can verify composition, while water content and residual counterion measurements support the mass balance of a batch. Stability studies under accelerated conditions are used to estimate shelf life, though such estimates carry uncertainty for long-term storage.
Material supplied for research use is normally a white to off-white lyophilized powder. The solid is hygroscopic and is handled in a low-humidity environment to limit water uptake. Bulk quantities are frequently shipped in sealed vials under inert gas. Once reconstituted in water or a neutral buffer, the solution is less stable than the dry powder and is usually divided into single-use aliquots.
This was a boom year with a record high in exports, but the Scotch Whisky Association expressed concern for the future, particularly "the challenges posed by Brexit and by tensions in the global trading system". Scotch whisky tourism has developed around the industry, with distilleries being the third most visited attraction in Scotland; roughly 2 million visits were recorded in 2018. Some 68 distilleries operate visitors' centres in Scotland and another eight accept visits by appointment. Hotels, restaurants, and other facilities are also impacted by the tourism phenomenon. Tourism has had an especially visible impact on the economy in some remote rural areas, according to Fiona Hyslop MSP, Cabinet Secretary for Culture, Tourism and External Affairs: "The Scottish Government is committed to working with partners like the Scotch Whisky Association to increase our tourism offer and encourage more people to visit our distilleries." During the COVID-19 pandemic, exports of many food and drink products from the UK declined significantly, and that included Scotch whisky. Distillers were required to close for some time and the hospitality industry worldwide experienced a major slump. According to news reports in February 2021, the Scotch whisky sector had experienced £1.1 billion in lost sales. Exports to the US were also affected by the 25% tariff that had been imposed. Scotch whisky exports to the US during 2020 reportedly fell by 32% from the previous year. Worldwide exports fell in 70% of Scotch whisky's global markets.
The attack killed two workers from the rescue force and destroyed an ambulance. Other attacks on Islamic Health Authority centers occurred in Kafr Kila, Odaisseh and Blida killed seven paramedic and rescue workers and destroyed 17 ambulances. On 27 March 2024, an Israeli airstrike targeted a paramedic center affiliated with the Islamic Group in Hebbariye, killing seven volunteer paramedics. The airstrike was condemned by the Lebanese Ministry of Health. Later in the day, Israeli airstrikes in Tayr Harfa killed two paramedics from the Islamic Health Society, while strikes in Naqoura killed one from the Amal Movement-affiliated Islamic Risala Scout Association. On 7 May 2024, Human Rights Watch declared the 27 March incident as an unlawful attack on civilians and said that they did not find any evidence of military targets at the site that was targeted. Investigations also showed that the IDF used an MPR 500 missile to conduct the raid. On 27 May 2024, an Israeli airstrike near Salah Ghandour Hospital in Bint Jbeil killed three civilians. WHO in Lebanon condemned the attack and called for the protection of hospitals and healthcare workers. In October 2024, the head of Lebanon's Civil Defence in the south said Israel was specifically attacking health workers, stating, "We have had 40 ambulances which have been completely destroyed. On top of that 24 rescuing stations have been hit - just in this area." Lebanese health officials stated on 5 October 2024 that fifty health officials had been killed in the prior 72 hours.
Deep geological repository Dry cask storage Deep borehole disposal – not implemented. Rock melting – not implemented. Ocean disposal – used by the USSR, the United Kingdom, Switzerland, the United States, Belgium, France, the Netherlands, Japan, Sweden, Russia, Germany, Italy and South Korea (1954–1993). This is no longer permitted by international agreements. Disposal in ice sheets – rejected in Antarctic Treaty. Deep well injection – used by USSR and USA. Nuclear transmutation, using neutron capture to convert the unstable atoms to those with shorter half-lives. Nuclear reprocessing such as the PUREX process allows for reuse of some radioactive materials. Disposal in outer space – not implemented as too expensive. In the United States, waste management policy broke down with the ending of work on the incomplete Yucca Mountain Repository. At present there are 70 nuclear power plant sites where spent fuel is stored. A Blue Ribbon Commission was appointed by U.S. President Obama to look into future options for this and future waste. A deep geological repository seems to be favored. Ducrete, Saltcrete, and Synroc are methods for immobilizing nuclear waste. Maritime transport of radioactive waste on ships is regulated at sea by the INF Code.
== GLP-1 and GIP receptor dual agonists == Tirzepatide is a dual agonist, targeting the GLP-1 and GIP receptors and given as a once-weekly injection. The FDA approved it for type 2 diabetes in May 2022. In the SURPASS-2 clinical trial, tirzepatide was compared directly against semaglutide, a GLP-1 mono-agonist, in nearly 1,900 adults with type 2 diabetes. Tirzepatide outperformed semaglutide at all doses in both reducing blood sugar and weight loss. At the highest dose, 60% of patients on tirzepatide achieved good blood sugar control and at least 10% weight loss, compared to only 22% of patients that did so on semaglutide. Side effects were mostly mild gastrointestinal symptoms, similar to other drugs in the GLP-1 class.
Peptidoglycan (PG) is a mesh-like structure containing polysaccharides cross-linked by peptide chains. Penicillin-binding proteins (DD-transpeptidases), in short PBPs, recognize the PG peptides and catalyze the cross-linking reactions. These enzymes are reported to have high specificity toward the chirality center of the amino acid backbone (D-chiral center) but relatively low specificity toward the side-chain structure. Therefore, when FDAAs are present, they are taken by PBPs for the cross-linking reactions, resulting in their incorporation into the PG peptide chains. At proper concentration, e.g. 1–2 mM, FDAAs labeling does not affect PG synthesis and cell growth because only 1%–2% of PG peptide chains are labeled with FDAA.
Sources: en.wikipedia.org
== Examples == In the built environment, evaporation limited capillary penetration is responsible for the phenomenon of rising damp in concrete and masonry, while in industry and diagnostic medicine this phenomenon is increasingly being harnessed in the field of paper-based microfluidics.
Carbon fixation is a biochemical process by which atmospheric carbon dioxide is incorporated by plants, algae and cyanobacteria into energy-rich organic molecules such as glucose, thus creating their own food by photosynthesis. Photosynthesis uses carbon dioxide and water to produce sugars from which other organic compounds can be constructed, and oxygen is produced as a by-product. Ribulose-1,5-bisphosphate carboxylase oxygenase, commonly abbreviated to RuBisCO, is the enzyme involved in the first major step of carbon fixation, the production of two molecules of 3-phosphoglycerate from CO2 and ribulose bisphosphate, as shown in the diagram at left. RuBisCO is thought to be the single most abundant protein on Earth.
Piston syringes were used in ancient times. During the 1st century AD Aulus Cornelius Celsus mentioned the use of them to treat medical complications in his De Medicina. 9th century: The Iraqi/Egyptian surgeon Ammar ibn 'Ali al-Mawsili' described a syringe in the 9th century using a hollow glass tube, and suction to remove cataracts from patients' eyes, a practice that remained in use until at least the 13th century. Pre-Columbian Native Americans created early hypodermic needles and syringes using "hollow bird bones and small animal bladders". 1650: Blaise Pascal invented a syringe (not necessarily hypodermic) as an application of what is now called Pascal's law. 1844: Irish physician Francis Rynd invented the hollow needle and used it to make the first recorded subcutaneous injections, specifically a sedative to treat neuralgia. 1853: Charles Pravaz and Alexander Wood independently developed medical syringes with a needle fine enough to pierce the skin. Pravaz's syringe was made of silver and used a screw mechanism to dispense fluids. Wood's syringe was made of glass, enabling its contents to be seen and measured, and used a plunger to inject them. It is effectively the syringe that is used today. 1865: Charles Hunter coined the term "hypodermic", and developed an improvement to the syringe that locked the needle into place so that it would not be ejected from the end of the syringe when the plunger was depressed, and published research indicating that injections of pain relief could be given anywhere in the body, not just in the area of pain, and still be effective.
The mutation alters the structure and function of skeletal muscles producing one of three forms of myopathy: type 3 nemaline myopathy, congenital myopathy with an excess of thin myofilaments (CM) and congenital myopathy with fibre type disproportion (CMFTD). Mutations have also been found that produce core myopathies. Although their phenotypes are similar, in addition to typical nemaline myopathy some specialists distinguish another type of myopathy called actinic nemaline myopathy. In the former, clumps of actin form instead of the typical rods. It is important to state that a patient can show more than one of these phenotypes in a biopsy. The most common symptoms consist of a typical facial morphology (myopathic facies), muscular weakness, a delay in motor development and respiratory difficulties. The course of the illness, its gravity, and the age at which it appears are all variable and overlapping forms of myopathy are also found. A symptom of nemaline myopathy is that "nemaline rods" appear in differing places in type 1 muscle fibres. These rods are non-pathognomonic structures that have a similar composition to the Z disks found in the sarcomere. The pathogenesis of this myopathy is very varied. Many mutations occur in the region of actin's indentation near to its nucleotide binding sites, while others occur in Domain 2, or in the areas where interaction occurs with associated proteins. This goes some way to explain the great variety of clumps that form in these cases, such as Nemaline or Intranuclear Bodies or Zebra Bodies.
=== Classification of antivirals based on target === Classifying antivirals based on their target of action, the protein or process that they interact with, serves to create two broad categories of antivirals: direct-acting antivirals (DAAs) and host-targeting antivirals (HTAs).
Sources: en.wikipedia.org
=== P. s. pv. actinidiae === Mesarich et al. 2017 provides several libraries for transposon insertion sequencing of mutants of P. s. a. The kiwifruit industry in New Zealand has suffered catastrophic losses since their first known outbreak in 2007 from P. syringae pv. actinidiae. New Zealand is second to Italy in the total volume of kiwifruit exports making an annual revenue of $NZ 1 billion, making it the most economically valuable export in the country. In 2014 the loss of exports alone was as high as NZ$930 million. Growers had to pay for treatments, and removal of infected vines along with suffering the loss of capital value in their orchards. For some, the orchard values went from NZ$450,000/ha to $70,000/ha after the outbreak, which is the price of bare land. The total loss of equity for the country of New Zealand was as high as NZ$2 billion. Between 2010 and 2012 over 2,000 hectares (4,900 acres) of Italian kiwifruit orchards either were killed by P. syringae pv. actinidiae or were killed to contain the disease. The financial consequences for growers and their suppliers were severe, as were the economic consequences more widely.
== Pharmacology in pain == Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage. It is an essential defensive function where pain works as an alarm to avoid or limit tissue damage. Its neurobiology is complex, and involves stimulation of several different types of nerves. Opioids act upon opioid receptors that are coupled to inhibitor G protein coupled receptors (GPCR). These receptors fall into 3 classes: μ (mu), δ (delta), and κ (kappa) receptors. More than 70% of opioid receptors are μ receptors, predominantly located on the central terminals of nociceptors in the dorsal horn of the spinal cord. The remaining 30% of opioid receptors are located post-synaptically on dendrites of second-order spinothalamic neurons & interneurons. When an opiate binds as an agonist to the GPCR, there will be a signaling cascade resulting in the inhibition of adenylate cyclase and calcium ion channels with the stimulation of potassium ion channels. The net effect of these changes is a reduced intracellular cAMP and hyperpolarization of the neuronal cell reducing neurotransmitter release. Through this pathway, when opiates bind to and activate the mu receptor, there is a decrease transmission of pain signalling. This pathway targeted for the analgesia properties that opiates are known and used for. Other clinically important roles of mu are its involvement in respiratory and cardiovascular functions, gastrointestinal peristalsis, feeding, and mood.
However, there was indication of a small effect in improving depressive symptoms that approached trend-level significance. lisdexamfetamine was well-tolerated in the meta-analysis. The quantity of evidence was limited, with only four trials included. In a subsequent 2022 network meta-analysis, lisdexamfetamine was significantly effective as an antidepressant augmentation for treatment-resistant depression. Although lisdexamfetamine has shown limited effectiveness in the treatment of depression in clinical trials, a phase II clinical study found that the addition of lisdexamfetamine to an antidepressant improved executive dysfunction in people with mild major depressive disorder but persisting executive dysfunction.
== Types == Addiction is described in two broad forms: substance use disorders, which involve psychoactive drugs, and behavioral addictions, which involve activities that produce reward without a drug. Whether some patterns of eating meet the criteria for addiction remains disputed.
=== Badger's rule === For many kinds of samples, the assignments are known, i.e. which bond deformation(s) are associated with which frequency. In such cases further information can be gleaned about the strength on a bond, relying on the empirical guideline called Badger's rule. Originally published by Richard McLean Badger in 1934, this rule states that the strength of a bond (in terms of force constant) correlates with the bond length. That is, increase in bond strength leads to corresponding bond shortening and vice versa.
Sources: en.wikipedia.org
It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.
In animal studies it showed greater selectivity for growth hormone release, with less effect on cortisol and adrenocorticotropic hormone than compounds such as GHRP-6. This selectivity is one of the most frequently cited features in preclinical literature. Whether the same profile applies in other contexts is not fully established.
The receptor-level events are reasonably well described, but the full range of downstream effects is not. Studies have reported activity in tissues beyond the pituitary, including the gut. How these observations translate across species and conditions remains an open question.
It has not been approved as a therapeutic by major regulators, and the human trial record is small and dated. Material available today is mostly sold as a research chemical for laboratory use. Approval and restriction status varies by country.